Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda says Basen data is meaningful

Takeda says Basen data is meaningful

24th April 2009

Takeda’s data from its phase III clinical trial of Basen is “very meaningful”, it has claimed.

Published in the medical journal the Lancet, the research looks at how effective the drug is at aiding postprandial hyperglycemia in diabetes mellitus.

It was found to offset the condition in those patients with impaired glucose tolerance when used in addition to exercise and dietary treatment.

Lead author of the paper Dr Ryuzo Kawamori said the drug had preventative effects of type 2 diabetes, adding he was pleased to have the article in print.

“It is very gratifying that the clinical data of voglibose is published in such an authoritative medical journal the Lancet,” he remarked.

Earlier this month, Takeda discontinued clinical trials of a compound ? called TAK-379 ? designed to treat diabetes.

It was under development in Europe, the US and Japan but did not meet criteria to support any additional investigational studies.

The pharmaceutical company asserted it would continue its in-house research and development activities in order to enhance its pipeline.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.